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ABSTRACT OF THE THESIS TITLED “EXPRESSION AND 
CLINICOPATHOLOGIC CORRELATION OF BASAL CYTOKERATINS IN 
BREAST CANCER”  
Introduction: Treatment for breast cancer is based on the expression of the 
immunomarkers such as ER, PR and  HER2/neu. Cases which are negative to all the three 
immunomarkers, are called Triple Negative Breast Cancers (TNBC) and they have a poor 
prognosis. Recent studies have shown that some of the TNBCs express cytokeratins      
CK 5/6 (subcategorizing them as basal-like breast cancers) and these respond well to 
anthracycline-based chemotherapy.  
Aim and Objectives: To study the expression of basal cytokeratins CK 5/6 in breast 
carcinomas reported in our centre and to correlate with histological type, grade, size, 
clinical features and ER, PR and HER2/neu status. 
Methods: Tissues of 44 cases of breast carcinoma diagnosed between June 2009 and May 
2014 were retrieved.  Immunohistochemical staining for CK 5/6 was done and it was 
correlated with parameters such as histopathological type, grade, size, invasion and ER, 
PR and HER2/neu status. 
Results: Eight of the breast carcinomas (18%) were categorized as Triple Negative Breast 
Cancers (TNBC) as they were negative for ER, PR and HER2/neu. Four of the TNBCs 
(50%), were positive for CK 5/6. Significant statistical correlation was observed between 
the size of the tumour and positive CK 5/6 expression. All CK 5/6 positive cases were of 
high grade. 
Conclusion: The routine use of CK 5/6 is recommended in all cases of TNBCs, as 50% of 
them are positive for these markers. Patients in this subcategory could benefit from 
anthracycline-based chemotherapy.  
Key Words: Triple Negative Breast Cancers, Cytokeratin 5/6, basal-like breast carcinoma. 
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INTRODUCTION 
Breast cancers are a diverse group of diseases that vary remarkably in terms 
of clinical presentation, histology, behaviour and genetic characteristics.1 
Since the 1930s, there has been a steady increase in the incidence of breast 
cancers worldwide. This increase continued steadily into the early nineties. 
It contributes to 22% of all female malignancies worldwide (SEER 
committee) and 26% in the developed world.2 Globalization is now titling 
this balance; adaptation of a western lifestyle and improved access to 
diagnostic modalities has been implicated in the increased rates in Asia, 
including India.  
Two established reasons have been attributed to high rates of incidence. 
i) Increase in awareness and mammographic screening. 
ii) Use of hormone replacement therapy in post menopausal women.  
As per the WHO’s International Agency for Research on Cancer, the 
number of new cases of female breast cancers in India in the year 2012 was 
144,937. This figure is lesser than the number of women diagnosed in the 
USA in the same year (232,714). However, the mortality rate is nearly 50% 
in the Indian cohort whereas only one woman out 5-6 patients dies of breast 
cancer in the US.3 
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The WHO further stresses that India has the maximum mortality rate when 
compared to the other countries under study. Persistent efforts to improve 
diagnostic and therapeutic modalities have contributed to the relatively 
better cure rates in the USA. Thus, breast cancer research has become the 
need of the hour with introduction of more studies tailored to the Indian 
population.  
GLOBOCAN cancer fact sheet released in 2012 also shows that though the 
incidence is lesser, the burden is somewhat similar owing to India’s large 
population. Similarly, the mortality rate was devastatingly high. Even in 
2008, GLOBOCAN statistics showed that carcinoma cervix was the most 
common female cancer. It was estimated by the same agency that breast 
carcinomas would surpass and claim this dubious honour soon. Currently, 
breast carcinomas are the commonest cancers occuring in Indian females 
and contribute to 21.5% of all cancer deaths.3 
Pap screening and improved surgical techniques and chemotherapy has 
contributed to lowering the fatalities of cervical cancer. Similar results can 
be achieved in breast cancer by implementing early detection by compulsory 
mammography. However, with a 5-year prevalence rate of 22.2%, India has 
a sizeable population of women living with breast carcinomas. The treatment 
has been revolutionized by the introduction of targeted therapy. 
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Breast cancers that express Estrogen and Progesterone receptors can be 
treated by hormonal manipulation.4 Targeted therapy towards HER2/neu has 
great success and Trastuzumab has been introduced as an adjuvant drug in 
those showing overexpression of HER2neu.5 
A subset of breast cancers have been found to show no expression of any of 
the above mentioned markers. These have been labeled as Triple Negative 
Breast Cancers (TNBCs). Though hormonal manipulation is of no use in this 
subset, they have been found to show expression of other markers such as 
basal cytokeratins and EGFR.1 
They also have greater sensitivity to anthracycline-based chemotherapy6 
despite poor pathologic complete response. 
Our study focuses on identifying the cases of breast cancer at our centre and 
performing immunohistochemical studies of the basal cytokeratin CK 5/6 in 
them. We further propose to study their expression and correlate with 
various clinicopathological parameters. 
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AIMS AND OBJECTIVES 
1. To study the clinicopathological profile of invasive breast carcinomas 
diagnosed in the department of pathology during the study period. 
2. To categorize the tumours based on the histological type and grade. 
3. To observe the immunohistochemical expression of hormone 
receptors and HER2/neu in various categories of breast cancers. 
4. To analyze the expression of Cytokeratin CK 5/6 in breast cancers and 
correlate with clinical and pathological parameters. 
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REVIEW OF LITERATURE 
GROSS ANATOMY OF THE ADULT BREAST10:  
The mature adult breast rests on the pectoralis major muscle from which it is 
separated by the pectoralis fascia. It is situated with the long axis diagonal to 
the chest wall and extension into the axilla as the tail of Spence is seen. The 
boundaries of the breast are as follows: 
i. Laterally, it extends over Serratus anterior. 
ii. Inferiorly, over External oblique muscle and Superior rectus sheath 
iii. Medially, it is limited by the sternum. 
The superficial fascia is seen continuous with the cervical fascia superiorly 
and with the superficial abdominal fascia of Cooper inferiorly. Suspensory 
ligaments of Cooper, which anchor the skin and nipple to the breast, are 
fibrous strands extending from the dermis into the parenchyma. 
Retromammary space containing loose areolar tissue is formed by the space 
between the deep membranous layer superficial and the fascia of both 
pectoralis major and serratus anterior. The pectoralis major muscle extends 
into the dome-shaped pyramidal axillary space to form the axillary fascia. 
These anatomical landmarks are important during dissection for identifying 
neoplastic or inflammatory infiltrative processes. 
6 
 
The arterial supply of the breast is by the internal thoracic, axillary and 
intercostal arteries. The venous draining tends to be more varied, the 
superficial and deep venous complexes formed mainly by branches of the 
axillary and internal thoracic veins.  
Lymphatics of the breast mainly drain into the axillary nodes. This 
constitutes 75% of the overall lymphatic flow. Rotter’s nodes (located in the 
interpectoral fascia), internal thoracic nodes and posterior intercostal nodes 
constitute other areas of drainage. Drainage into supraclavicular, 
infraclavicular and intramammary nodes is also seen. 
FUNCTIONAL GROSS ANATOMY 
The breast parenchyma is composed of 15-25 lobes based on the major 
lactiferous ducts draining into the nipple. Each lobe consists of a complex 
morphofunctional unit composed of Terminal duct/lobule unit (TDLU) and 
the large duct system. The large ducts branch into TDLUs; the terminal duct 
further branches into a grape-like cluster of acini to form lobule. The TDLU 
is embedded in a myxoid-appearing, hormone responsive stroma with 
absence of elastic fibres while the larger duct is enveloped by less hormone-
responsive, elastic connective tissue. The breast parenchyma has variable 
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proportions of fat and stroma depending on age and individual 
predisposition. The plasticity is suggestive of hormonal regulation.11 
 The TDLU carries out the secretory activity of the mammary gland. It is 
formed by the lobule and terminal ductule, further connecting to the 
subsegmental duct, segmental duct and collecting (lacteriferous) duct in 
sequence. The unit then empties into the nipple. Beneath the nipple, the 
lacteriferous duct is dilated to form the lactiferous sinus. 
MICROSCOPIC ANATOMY 
The duct orifice, which opens out into the nipple, is lined by stratified 
squamous epithelium. The luminal aspect of the ductal-lobular system is 
lined by columnar or cuboidal cells. These cells are predominantly involved 
in secretory activity. Myoepithelial cells lie between the epithelial layer and 
the basal membrane, invading the luminal epithelium through slender 
processes. Spindle-shaped myoepithelial cells form a continuous layer, 
parallel to the long axis. These cells contract to assist milk flow during 
lactation. Toker cells are basally located clear cells which are related to 
Paget’s disease.12 
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The stroma shows sparse distribution of lymphocytes, plasma cells, mast 
cells and histiocytes. Periductal histiocytes, termed ochrocytes, are seen 
associated with inflammatory and proliferative conditions. 
The histology of the lobules is inconstant due to changes associated with 
menstruation, pregnancy, lactation, aging, menopause, and hormone intake. 
During pregnancy, increased number of secretory acini is seen as the 
terminal duct proliferates under the influence of the hormones oestrogen and 
progesterone. Prolactin, human chorionic somatomammotropin, thyroxine 
and corticosteroids also play an important role in proliferation of the breast. 
The lobules enlarge and the acini dilate, while the interlobular septa remain 
the same. The lining epithelium is cuboidal to low columnar vacuolated 
cells. The intralobular stroma is not as prominent and shows an influx of 
lymphocytes, plasma cells and eosinophils. The acini produce a protein-rich 
fluid called colostrum which dilates them further.  
In the puerperal period and during lactation, the prolactin activity which was 
suppressed during pregnancy by oestrogens and progesterone becomes 
predominant. Milk-distended acini form almost the entire breast. On 
histological examination, the acini are filled with vacuolated eosinophilic 
material and lined by flattened epithelium. At the end of lactation, the 
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epithelial cells undergo apoptosis and the lobules regress and atrophy. Even 
though a decrease in the size of the breast is noted, the number and size of 
lobules will be permanently increased. 
Menopause is associated with a sharp drop in levels of estrogen and 
progesterone. This hormonal alteration manifests in the breast with 
decreased in the cellularity and number of lobules along with epithelial 
atrophy. Shrinkage, as well as cystic dilation of the lobules is noted. 
Perivascular and periductal elastosis is seen. The breast of the elderly 
appears radiolucent.  
The nipple consists of large collecting ducts opening out through the 
lactiferous orifices. Sebaceous glands, independent of pilar unit can be seen. 
The stroma is dense and fibrous and ereticle smooth muscular tissue is seen 
embedded within it. 
Montgomery Tubercles are protuberances in the areola, numbering around 
ten to twenty. They are formed by lacteriferous ducts associated with a 
sebaceous apparatus. These become prominent during pregnancy and their 
epidermis shows increased melanin in the basal layer. 
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A few unusual conditions are seen in normal breast: 
1. Pregnancy-like changes in the absence of hormonal intake or 
pregnancy: The cells resemble those seen in Arias-Stella reaction 
(have abundant vacuolated cytoplasm and apically located large, 
hyperchromatic nuclei) while the lumen are dilated. An association 
has been found with in situ and invasive carcinoma. 
2. Clear cell change of ductal/lobular epithelium: also referred to as 
lamprocytosis10, this condition is associated with lobular enlargement. 
The lobules are lined by large clear cells almost obliterating the 
lumen. The cytoplasm is granular, vacuolated or clear and does not 
feature the “decapitation” secretion that is seen in pregnancy-induced 
changes. 
EMBROYOLOGY 
Mammary ridges (also called milk lines) are thickened endometrium on the 
ventral surface of a 5-week fetus that extends from axilla to upper medial 
portion of thigh. Most of the ridge involute usually but persistence has been 
noted in the form of ectopic mammary glandular tissue. 
At around 15 weeks of gestation, mesenchymal condensation occurs around 
the epithelial breast bud. Cords of epithelium grow down into the 
11 
 
mesenchyme and these develop into lobes. Fibrovascular tissue ensconcing 
the lobes evolves from the papillary layer of the fetal dermis. Myoepithelial 
cells are seen arising from basal cells. More collagenized stroma originates 
from the reticular dermis and encompasses the lobular architecture forming 
the suspensory ligaments of Cooper which anchor the breast parenchyma to 
the overlying skin. Adipocytic differentiation occurs between 20 and 32 
weeks. Towards the end of gestation, canalization of epithelial cords and 
branching of the glandular structures is seen. Mammary pit is the primitive 
homologue of the nipple. If the evagination of the mammary pit does not 
process normally, congenitally inverted nipple is seen. 
Testosterone influences breast development after 15th week. Towards the 
end, maternal and placental steroid hormones and prolactin induce secretory 
activity. Palpable breast enlargement and secretion of “witch’s milk” in the 
newborn is due to the persistence of these hormones in their circulation. 
After a month, this secretory activity subsides and the breast regresses into 
an inactive state until puberty. 
During puberty, thelarche occurs under the cyclical influence of estrogen 
and progesterone. Ducts proliferate and stromae differentiate on estrogenic 
stimulation. Lobule formation, which remained quiescent until the onset of 
ovulation is now initiated. Differentiation and growth is maximum during 
12 
 
adolescence and further accentuated during pregnancy. The adolescent male 
breast is composed of ducts lined by flattened epithelium in a fibroadipose 
stroma.2 
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CARCINOMA OF THE BREAST 
DEFINITION 
Invasive breast carcinomas are a group of malignant neoplasms that arise 
from the epithelium and tend to invade the adjacent tissue, lymph nodes and 
metastasize to distant sites. Adenocarcinomas, originating from the 
mammary parenchymal epithelium, are the highest in incidence. These 
carcinomas originate from the cells of the terminal duct lobular unit 
(TDLU). Breast carcinomas encompass a variety of morphological 
phenotypes and histological types, each of these with their own prognostic 
values.  
Breast carcinoma is the commonest non-skin malignancy seen in women 
worldwide. Most cancer deaths are attributed to breast carcinoma, second 
only to bronchogenic carcinoma. Statistics issued by the SEER committee in 
2012 shows that in the USA, nearly 226,000 women were diagnosed with 
invasive breast cancer, 63,000 with carcinoma in situ, and almost 40,000 
women succumbed to the disease2. Overall, it constitutes 22% of all 
malignancies in women worldwide. In developed and affluent countries, it 
accounts for 26% of all female cancers, the next common subtype having 
only half the incidence. The risk rates are much lesser in Eastern Asia and 
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Sub-Saharan African countries but a steady increase in incidence has been 
noted. This has been attributed to environmental factors, adoption of a 
western lifestyle (delayed pregnancy, fewer pregnancies and decreased 
breastfeeding) and improved access to diagnostic modalities.13 
Studies done in 1990 showed that the age-specific incidence rates varied 10-
fold worldwide. DCIS and smaller, stage I lesions have been detected more 
frequently since 1980, owing to the widespread use of mammography. 
A study done in reduction mammoplasty specimens by Dotto et al, taking 
516 consecutive cases showed 92 (18%) usual ductal hyperplasia (UDH), 28 
(5%) DIN1, 17 (3%) LIN and 1 (0.2%) tubular carcinoma. No cases of high-
grade DIN or invasive carcinoma were identified.14 
Even though these carcinomas can be seen in any age group, they are rare 
before the age of 25. The incidence increases after the age of 30 and the 
perimenopausal age group is most commonly affected. Hormonally 
responsive tumours are seen increasing with age while the incidence of ER-
negative cancers remains constant. Detection rates have increased in the 
post-menopausal age group due to 
i. Mammographic screening which preferentially detects ER-positive 
tumours.  
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ii. usage of post-menopausal hormone replacement therapy. Less than 
20% of cancers in this age group are ER-negative, Her2neu positive. 
The survival rates started improving during the 1970s, but implementation of 
population screening programs and neoadjuvant targeted therapy in the turn 
of the century has led to early diagnosis, successful treatment and remission. 
The mortality rate which was around 30% in 1994 has steeply declined and 
is now 20%.  
In a registry maintained by Cancer Institute (W.I.A.), Chennai between the 
years 2006 and 2008, breast cancers formed 26.3% of all malignancies in 
females, emphasizing the burden in the local population also.15  
Aetiology And Risk Factors 
These are as listed below: 
1. Germline mutations. 
2. First degree relatives with breast cancer:  
Even in the absence of a germline mutation, first degree relatives of 
those affected with breast carcinoma are found to be at an increased 
risk of the same. 
3. Menstrual history: 
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Early menarche and late menopause are two conditions associated 
with increased estrogenic exposure and hence, a higher risk of breast 
cancer. 
4. Reproductive history:  
The following factors have been implicated in breast carcinoma. 
i. nulliparity and infertility. 
ii. late age at first childbirth. 
iii. lack of breastfeeding      Lactation causes differentiation of the 
Terminal Duct Lobule Unit (TDLU) and suppresses ovulation. 
The protective impact of lactation is seen best in those who 
breastfed over long periods of time, preferably over two years. 
This is common practice in developing countries where 
frequent and longer periods of nursing can be seen. 
5. Exogenous hormones:  
The National Toxicology Program, in 2002 labeled estrogen a 
carcinogen.16 Post menopausal Hormone Replacement Treatment is 
associated with an increased risk of breast cancer, especially if 
estrogen is given in conjunction with progesterone for a long period. 
The tumours that have estrogen as the aetiology tend to be small ER-
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positive tumours. These findings are further accentuated by the 
decreased risk of developing breast cancer (up to 75%) in those who 
undergo oopherectomy. Tamoxifen (Selective Estrogen Receptor 
Modulator) and Aromatase inhibitors, both of which are associated 
with decreased risk of breast cancer. Oral contraceptives, which in the 
past have been implicated in the aetiogenesis of breast cancer, have 
been evaluated recently. The relative risk has been attributed to 
detection bias and found to be statistically insignificant.  
6. Nutrition:  
Earlier studies showed that a high-fat, meat-based diet increased the 
relative risk of breast cancer; this has led to many studies being 
conducted on a large scale. The conclusion has been that diet plays a 
minimal role in the aetiopathogenesis of breast carcinoma. However, 
post-menopausal obese women are at an increased risk, probably due 
to the excess fat deposits synthesizing estrogen. Younger obese 
women (<40 years) tend to have anovulatory cycles, with associated 
diseases such as PCOD. These women have lower progesterone levels 
and are at a decreased risk.  
7. Environmental Toxins:  
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Smoking and organochlorine pesticides are being investigated and 
their effects are inconclusive, as of now. Alcohol intake was found to 
cause a mild increase in breast carcinoma rates.  
8. Physical activity:  
Cohorts of individuals who have been active throughout their lifetime 
have been found to have decreased predisposition to malignancies. 
Additionally, physical activity has been found to confer some 
protection to post menopausal women. Post-menopausal women with 
a sedentary lifestyle and obesity develop insulin resistance. Increased 
insulin levels lead to elevation of sex steroids, particularly androgen 
and these are converted to estrogen in the adipose tissue. 
9. Benign Breast Disease:  
The absolute lifetime risk of developing breast cancer in patients with 
benign breast diseases are as follows 17:- 
i) Fibrocystic changes: 3% 
ii) Proliferative disease without atypia: 5 to 7% 
iii) Proliferative disease with atypia: 13 to 17% 
iv) Carcinoma in situ: 25 to 30% 
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10. Radiation exposure: 
People who have undergone radiation exposure in the form of cancer 
treatment regimens or nuclear accidents are at increased risk. This is 
especially relevant in young women who have undergone chest 
irradiation as part of Hodgkin’s lymphoma treatment protocol (20 to 
30% risk) 18 
 
11. Race/Ethinicity/Country of Birth:  
 The variation in the frequency of germline mutated genes leads to the 
 ethnicity divide. As stated earlier, the rates in developing nations, 
 although on a rise, are still lesser than the rates in the western world. 
12.  Contralateral breast/Endometrial carcinoma: 
 There is a 1% risk of developing breast cancer in the contralateral 
 breast in survivors. Endometrial carcinoma, which shares many risk 
 factors with breast carcinoma, is mostly due to prolonged estrogen 
 exposure.19 
13. Breast density: 
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 Increased density is associated with a 4 to 6-fold higher risk of breast 
 cancer. This tends to be familial and is also seen in people with less 
 parity, late childbirth and hormone replacement therapy. Failure of 
 involution causes increased breast density in the elderly. 
PATHOGENESIS 
   Breast cancers arise from cells with numerous genetic aberrations that are 
acquired by hormonal exposure or are inherited as germline mutations. The 
penetration of these genes further depends on other environmental factors. 
Sporadic cases, on the other hand, are not free from genetic factors. The 
aetiopathogenesis is complex and multifactorial, as elaborated earlier. 
Familial Breast cancers: 
13% of all breast cancers can be attributed to an identifiable inherited 
susceptibility gene or genes. This group is responsible for cancers that affect 
multiple first-degree relatives, the young and are multicentric.20 These 
tumour suppressor genes (BRCA1, BRCA2, TP53, and CHEK2) either 
undergo sporadic mutation or defective copies of these genes are inherited.21 
           A landmark event in the molecular study of breast cancer was the 
identification of BRCA genes. 16% of familial breast cancers are due to 
mutation of these genes, which are seen in certain ethnic populations such as 
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Ashkenazi Jews (up to 2% affected). Carriers of the mutated genes have a 70 
to 80% risk of developing breast cancer by 70 years of age. 
80 to 90% of single gene familial breast cancers and roughly 3% of all breast 
cancers are due to BRCA1 and BRCA2 mutations. 
BRCA1 mutations also predispose to the development of ovarian cancer 
(nearly 20 to 40% of cancers). BRCA 2 is seen more commonly in male 
breast cancer. BRCA1 encoded protein works in the following ways to 
suppress tumorigenesis:- 
i) homologous recombination DNA repair 
ii) Checkpoint control of cell cycle 
iii)  Ubiquitylation 
iv) Chromatin remodeling 
v) DNA decatenation 
BRCA 2 protein is responsible for DNA repair, cytokinesis and meiosis. 
Loss of repair function of DNA double-stranded breaks result in tumours 
with medullary features; i.e, high grade, high mitotic rate, necrosis, ‘triple 
negative’ with a basal-like gene expression and TP53 mutation. BRCA2 
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mutation associated cancers tend to be more heterogenous and are hormone-
receptors positive. 
Fewer than 1% of familial breast cancers are caused by mutations in the 
following tumour suppressor genes i)PTEN (Cowden) ii)STK11 (Peutz-
Jeghers) iii)ATM (Ataxia Telengectasia) 
8% of familial breast cancers are a consequence of germline mutations in 
TP53 and CHEK2. Genomic integrity is maintained by aforementioned 
tumour suppressor genes. Once mutated, the cell either undergoes apoptosis 
or is repaired. ATM detects damage and along with p53 and CHEK 2, causes 
arrest of the cell cycle. CHEK 2 and both BRCA genes repair double 
stranded DNA breaks. Impairment of any of the above genes result in 
propagating cells with permanent DNA damage.22 
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MOLECULAR SUBTYPES OF INVASIVE BREAST CANCER23 
 Luminal A Luminal B HER2/neu Basal-like 
Pattern of gene 
expression 
Luminal cytokeratins 
and hormone 
receptors-high 
expression 
Expression of 
luminal cytokeratins 
seen. Expression of 
hormone receptors 
and related genes-
moderate to weak. 
Low expression 
of ER. High 
expression of 
HER2/neu and 
17q12 
High expression of 
basal cytokeratins 
and epithelial genes. 
Low expression of 
hormone receptors 
Clinical and biological 
features 
ER/PR-positive. 
HER2/neu- negative.
ER/PR-positive. 
HER2/neu 
expression-variably 
positive. Higher 
grade and 
proliferation than 
Luminal A 
 
ER/PR negative. 
HER2/neu 
positive. High 
grade, TP53 
mutations 
present and 
higher likelihood 
of nodal 
metastasis
Triple-negative (ER, 
PR, HER2/neu) 
TP53, BRCA1 
mutations seen.  
Histological correlation Tubular carcinoma,
Cribriform 
carcinoma, 
IDC, NOS
Classic lobular 
carcinoma 
Micropapillary 
carcinoma 
High grade IDC, 
NOS 
High grade IDC 
Metaplastic and 
medullary 
carcinoma 
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Treatment Response to 
endocrine therapy-
good. 
Response to 
endocrine therapy-> 
less satisfactory 
than Luminal A 
Responds to 
Trastuzumab 
No response to 
endocrine therapy or 
Trastuzumab 
Chemotherapy Response is variable Response better 
than that of Luminal 
A 
Responds to 
anthracycline-
based 
chemotherapy
Responds to 
Cisplatin and PARP 
inhibitors 
Prognosis Good Not as good as 
luminal A
Generally poor Generally poor 
Immunomarkers ER and/or PR+ ER and/or PR+ ER, PR- 
HER2+
ER, PR, HER2 – 
CK5/6 or EGFR +
25 
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HISTOLOGICAL SUBTYPES OF BREAST CARCINOMA: 
 WHO histological classification of tumours of the breast13 
Epithelial tumours: 
Invasive ductal carcinoma, not otherwise specified 
Mixed type carcinoma 
Pleomorphic carcinoma 
Carcinoma with osteoclastic giant cells 
Carcinoma with choriocarcinomatous features 
Carcinoma with melanotic features 
Invasive lobular carcinoma 
Tubular carcinoma 
Invasive cribriform carcinoma 
Medullary carcinoma 
Mucinous carcinoma and other tumours with abundant mucin 
Mucinous carcinoma 
Cystadenocarcinoma and columnar cell mucinous carcinoma 
Signet ring cell carcinoma 
Neuroendocrine tumours 
Solid neuroendocrine carcinoma 
Atypical carcinoid tumour 
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Small cell / oat cell carcinoma 
Large cell neuroendocrine carcinoma 
Invasive papillary carcinoma 
Invasive micropapillary carcinoma 
Apocrine carcinoma 
Metaplastic carcinomas 
Pure epithelial metaplastic carcinomas 
     Squamous cell carcinoma 
     Adenocarcinoma with spindle cell metaplasia 
     Adenosquamous carcinoma 
     Mucoepidermoid carcinoma 
Mixed epithelial/mesenchymal metaplastic carcinomas 
Lipid-rich carcinoma 
Secretory carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen-rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
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Lobular neoplasia 
Lobular carcinoma in situ 
Intraductal proliferative lesions 
Usual ductal hyperplasia 
Flat epithelial atypia 
Atypical ductal hyperplasia 
Ductal carcinoma in situ 
Microinvasive carcinoma 
Intraductal papillary neoplasms 
Central papilloma 
Peripheral papilloma 
Atypical papilloma 
Intraductal papillary carcinoma 
Intracystic papillary carcinoma 
Benign epithelial proliferations 
Adenosis including variants 
Sclerosing adenosis 
Apocrine adenosis 
Blunt duct adenosis 
Microglandular adenosis 
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Adenomyoepithelial adenosis 
Radial scar / complex sclerosing lesion 
Adenomas 
Tubular adenoma 
Lactating adenoma 
Apocrine adenoma 
Pleomorphic adenoma 
Ductal adenoma 
 
Myoepithelial lesions 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma 
Malignant myoepithelioma 
Mesenchymal tumours  
Haemangioma 
Angiomatosis 
Haemangiopericytoma 
Pseudoangiomatous stromal hyperplasia 
Myofibroblastoma 
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Fibromatosis (aggressive) 
Inflammatory myofibroblastic tumour 
Lipoma 
Angiolipoma 
Granular cell tumour 
Neurofibroma  
Schwannoma 
Angiosarcoma 
Liposarcoma 
Rhabdomyosarcoma 
Osteosarcoma 
Leiomyoma 
Leiomyosarcoma 
 
Fibroepithelial tumours 
Fibroadenoma 
Phyllodes tumour 
Benign  
Borderline 
Malignant 
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Periductal stromal sarcoma, low grade 
Mammary hamartoma 
Tumours of the nipple 
Nipple adenoma 
Syringomatous adenoma 
Paget disease of the nipple 
Malignant lymphoma 
Diffuse large B-cell lymphoma 
Burkitt lymphoma 
Extranodal marginal-zone B-cell lymphoma of MALT type 
Follicular lymphoma 
Metastatic tumours 
Tumours of the male breast 
Gynaecomastia 
Carcinoma 
Invasive 
In situ 
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Invasive ductal carcinoma, Not Otherwise Specified 
IDC, NOS are tumours that express components of specialized subtypes but 
are not in entirety, the tumour as a whole. Microscopic foci of 
tubular/medullary/metaplastic/colloid and apocrine carcinoma may be seen 
within a single tumour. 
The two main determinants are the histological origins of the tumour. 
1. Cell of origin: they are classified as ductal or lobular. 
2. a. epithelial (in situ) 
b. stroma (invasive) 
Ductal Carcinoma In Situ (DCIS) 
DCIS is a malignancy of ductal and lobular epithelial cells that are limited 
by the basement membrance. This spreads through the ductal system, 
extensively involving breast sectors. 
This is more easily picked up by mammography, which serves as a screening 
tool for early lesions of breast carcinoma. The only symptoms associated 
with DCIS are nipple discharge and a vague palpable mass (owing to 
periductal fibrosis). 
33 
 
The architecture is not as predictive of the outcome as the degree of 
cytological atypia. Younger women tend to be more symptomatic with 
extensive involvement and lobular cancerization. 
Types of DCIS: 
The morphological subtypes are grouped under high-grade 
comedocarcinomas and low grade DCIS. 
Comedocarcinoma: 
These lesions are associated with larger size, central location and 
multicentricity. On gross, the lesion is composed of thick-walled ducts with 
intervening normal breast parenchyma. On compression, necrotic plugs 
extrude from the centre. 
Microscopically, the lesion is composed of ducts with pleomorphic              
cells arranged in solid sheets with abundant mitoses. The ducts are widened 
with a central necrotic focus. Concentric fibrosis is seen surrounding the 
ducts with a preserved myoepithelial compartment. Comedocarcinomas and 
other subtypes which are ER, PR negative and have aneuploidy fall under 
Grade III. 
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All cases of comedocarcinoma have to be assessed for: 
i) degree of intraductal spread. 
ii) Stromal invasion. 
These should be extensively searched for and if present, the relative 
proportions of the in situ and invasive components have to be calculated. 
If the intraductal component exceeds 25% or more of the infiltrating tumour, 
the term Extensive Intraductal carcinoma has been recommended. A study 
showed that 21% of DCIS have an occult focus of invasion. This explains 
the presence of lymph node metastasis without a palpable primary. 
Low Grade DCIS 
These lack central necrosis and severe nuclear atypia. The following 
subtypes can be appreciated on histological examination. 
i) (In situ) Papillary carcinoma: 
On gross, they present as a well-circumscribed mass which may undergo 
cystic change on occasion. These have to be clearly distinguished from the 
more common papillomas and other benign lesions. Microscopically, these 
tumours have cells that are uniform in size and shape with large 
hyperchromatic nuclei exhibiting frequent mitoses. There is absence of 
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apocrine metaplasia, myoepithelial cells, other architectural patterns and 
benign breast disease. Lack of stroma favours papillary carcinoma. Solid, 
micropapillary and papillary carcinoma with transitional type epithelium are 
the variants described in literature. The micropapillary variant consists of 
papillae lacking a central fibrovascular core. 
ii) Solid DCIS: 
The lumina are filled with proliferating neoplastic cells that are larger than 
LCIS cells. These cells have prominent cytoplasmic borders and a more 
uniform nuclear morphology. 
iii) Cribriform DCIS: 
These are associated with the formation of uniform round spaces with the 
tumour clusters, imparting a sieve-like or cookie-cutter appearance. Roman 
bridges and trabecular bars are noted occasionally. 
iv) Clinging carcinoma  
is a controversial variant that shows malignant cells lining glands in one or 
two layers. The higher graded tumours are associated with individual cell 
necrosis. 
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Lobular cancerization is the phenomenon where an identifiable lobule 
shows features of DCIS.  
Any case of DCIS must be thoroughly examined, especially if worrisome 
features are present e.g. nuclear debris, cell ghosts, inspissated secretions 
and necrosis. Any of the following outcomes may be seen: 
1. May not transform into invasive cancer within the lifespan of the 
individual. 
2. Grades and cytological atypia dictate the disease progression. 
3. Invasive breast cancer may result without undergoing the sequence 
from DCIS. 
Lobular Carcinoma in situ: 
This condition is incidentally discovered and has high rates of 
multicentricity (70% of the cases) and bilaterality (30 to 40%). Also called 
lobular neoplasia, the histological examination of these tumours show 
distension of the lobules which are filled with uniform, small round cells 
with monomorphic nuclei. These cells are dyscohesive, a feature attributed 
to the loss of E-cadherin, a tumour suppressing adhesion protein. Pagetoid 
spread can be seen, but there is no skin involvement, necrosis or 
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calcification in these tumours. They tend to be ER/PR positive and HER2/ 
neu negative.  
Invasive carcinoma may eventually develop ib 25-30% of women, with the 
risk being high in both ipsilateral as well as the contralateral breast. 
Microinvasive carcinoma13 
These tumours are predominantly non-invasive, but one or more small 
infiltrative foci are seen into the stroma. They occur in conjunction with 
DCIS and account for less than one percent of all breast cancers. 
Histologically, they are described as tumours that are less than or equal to 1 
mm size. The stroma shows periductal lymphocytic infiltrate or 
desmosplasia and there is preserved basement membrane. 
Invasive Ductal Carcinomas, Not Otherwise Specified 
These are a heteregenous group of tumours that do not exhibit specific 
characteristics to denote a histological subtype. These neoplasms account to 
between 40 to 75% of all breast cancers.24 
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Macroscopy: 
They vary in size from 0.1 to 10 cm. On gross, they are vaguely 
circumscribed with stellate configuration. The cut surface is grey white, firm 
and gritty. 
Histopathology: 
Microscopic features of these tumours are highly variable. The atypical cells 
are arranged in groups, trabeculae or in solid/synctial pattern. Single file 
appearance may be appreciated but the cytological features differ from 
lobular carcinoma. The nuclear features here tend to be pleomorphic with 
variability in the mitotic figures. Foci of DCIS are often seen (up to 80% of 
the cases). 
Mixed type carcinoma: 
After relevant sampling and thorough histological examination, a tumour is 
classified as ductal, NOS if the pattern is seen in over 50% of its mass. If the 
ductal component forms 10 to 49% of the tumour, it is classified as either 
mixed ductal and lobular or mixed ductal and specific tumour subtype. 
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Pleomorphic carcinoma: 
This variant of ductal carcinoma occurs and is composed of pleomorphic 
tumour cells, with bizarre and giant forms comprising more than half of the 
tumour, superimposed on a background of pure adenocarcinoma or 
spindle/squamous differentiation. These tumours have a high rate of 
metastasis, lymphovascular invasion, cavitation and necrosis. Giant cells 
comprise more than 75% of tumour cells. They are classified as Grade 3 
malignancies. Mitoses are increased and these tumours are negative for ER, 
PR and positive for TP53 and S100. 
Carcinoma with osteoclastic giant cells: 
These tumours have stromal osteoblastic giant cells and are associated with 
inflammation and increased vascularity. The carcinomatous component is 
IDC usually with the giant cells interspersed with the gland formation or are 
seen forming rosettes around the neoplastic cells. 
The prognosis is similar to, or even better than Infiltrating Ductal 
Carcinoma, NOS. The osteoclasts are believed to originate from Tumour 
Associated Macrophages (TAMs). 
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Carcinoma with choriocarcinomatous features: 
In some instances, patients with IDC, NOS had high serum levels of beta-
HCG with nearly 60% of the tumour cells taking up the beta-HCG stain, on 
immunohistochemical studies. Histological differentiation is however rare 
and this subtype is seen in women in the sixth and seventh decade. 
Carcinoma with melanotic features:25 
Cases of breast parenchymal tumour with components of both ductal 
carcinoma and malignant melanoma have been reported. The presence of 
melanin by itself could be due to epidermal invasion and not a sign of tissue 
differentiation. Most breast melanotic tumours are secondary deposits. 
Prognosis of IDC: 
It depends on variables such as grade, size of the tumour, lymphovascular 
invasion and hormone and growth factor receptor positivity25. Various 
studies have shown that the 10-year survival rate is between 35 and 50%. 70 
to 80% of the tumours are ER positive and only 15-30% is HER2neu 
positive. 
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INVASIVE LOBULAR CARCINOMA 
These tumours are composed of dispersed cells arranged single or in linear 
cords (“single file” pattern) in a fibrous stroma. They form 5-15% of all 
breast carcinomas. These tumours have been peaking over the last twenty 
years in older women and this has been attributed to post-menopausal 
hormone replacement therapy. Mammographically, these tumours have 
distorted architecture and lack microcalcification. Bilaterality and 
multicentricity is frequently observed. 
Macroscopy: 
These tumours are poorly circumscribed due to the diffuse pattern of the 
neoplastic cells. Invasive Lobular Carcinomas are larger than their ductal 
counterparts. 
Microscopy: 
These neoplastic cells are small, uniform and are dispersed singly or in 
“Indian-file” pattern. Periductal concentric whorls may be seen. These cells 
have round nuclei, scant cytoplasm, occasionally with mucoid inclusions. 
LCIS is seen 90% of the cases. Mitoses are rare. 
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Variants: 
i. Solid pattern. 
ii. Alveolar variant: clusters of at least twenty cells with the 
cytomorphology that of lobular carcinoma 
iii. Pleomorphic lobular carcinoma: 
These variants have high degree of atypia. Signet ring cells, 
apocrine or histiocytoid differentiation may be seen. 
iv. Tubulolobular carcinoma (TLC): while the cytomorphology is 
essentially that of lobular carcinoma, these cells are found in a tubular 
pattern. In contrast to pure tubular carcinoma, TLC if found associated 
with an increased rate of axillary metastasis. E-cadherin status helps 
in making the differentiation.  
Immunohistochemistry: 
70 to 95% ER positivity rate is observed, higher than that of Infiltrating 
Ductal Carcinoma, NOS. The rate is 100% in the Alveolar variant and low 
(10%) in Pleomorphic type. PR and HER2/neu expression is lower in 
Infiltrating lobular carcinoma than their ductal counterparts. 
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Genetics: 
E (epithelial)-cadherin gene has the following functions: 
i) maintains cohesion between the epithelial cells 
ii) cell differentiation and tumour suppression factor. 
Deletion of 16q results in loss of E-cadherin expression and this is the 
striking feature of lobular carcinoma.26 Loss of E-cadherin expression and 
heterozygosity of 16q can also be seen in LCIS and Mixed ductal-lobular 
carcinoma. 
Prognosis of Lobular carcinoma: 
ILC tend to metastasize to bone, GIT, the female genital tract and meninges. 
In contrast, Infiltrating Ductal Carcinoma involves the lungs and has a 
higher rate of axillary nodal metastasis. 
The prognosis is better in the classical type than in the variants. 
Tubular  Carcinoma 
These account to less than 2% of all invasive breast cancers. On 
mammography, their spicular nature leads to early detection. These small-
sized tumours tend to occur in older women with lesser chances of nodal 
metastases.  
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Macroscopy:  
Most tumours measure less than 1 cm across. The pure type has a stellate 
configuration with central yellowish areas (indicative of stromal elastosis) 
while the sclerosing type is more poorly defined. 
Microscopy:  
The neoplasm is made up of tubules lined by a single layer of cells with 
clear lumina. Majority are rounded with occasional angulation. Minimal 
pleomorphism is noted. Tubular carcinoma is effectively ruled out if marked 
pleomorphism or multilayering is noted despite the characteristic 
architecture. Myoepithelial cells are not seen. The stroma is desmoplastic 
with occasional calcification.  Controversy prevails over the percentage cut 
off of tubular architecture needed to establish diagnosis. Current WHO 
advises that a 90% purity should warrant the diagnosis of tubular carcinoma 
while those having 50 to 90% should be considered mixed-type. 
Immunohistochemistry: 
ER and PR are generally positive while HER2 and EGFR are usually 
negative. 
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Prognostically, this subtype is associated with excellent prognosis on long-
term follow-up. Recurrence and metastasis is rare. 
INVASIVE CRIBRIFORM CARCINOMA 
The growth pattern in the pure form of these tumours consists almost 
entirely of invasive cribriform pattern. Less than 50% is of tubular pattern. 
The cells are arranged in islands which have a sieve-like or cookie-cutter 
appearance. Apical snouting and infrequent mitoses is seen. Desmoplasia is 
often observed. Minor tubular component (forming less than 50% of the 
tumour) is allowed. However, if carcinomas other than tubular form a 
component, they are referred to as mixed carcinomas.27 100% and 69% of 
cribriform carcinomas are ER and PR positive, respectively. 
Adenoid cystic and carcinoid are considered in the differentials. Adenoid 
cystic tumours have admixed myoepithelial cell population and luminal 
secretions while carcinoid are identified by the presence of argyrophilic 
granules. Cribriform DCIS have an intact myoepithelial layer and are more 
contained. 
Prognosis: the outcome in patients with these tumours has been very 
favourable, especially when compared with IDCs. 
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MEDULLARY CARCINOMA:  
These tumours are well-circumscribed and are composed of diffuse sheets of 
cells with no glandular arrangement, lacking stroma and with a dense 
lymphoplasmacytic infiltration. Women in the fifth decade of life are 
commonly affected, with these tumours accounting to 17% of all breast 
carcinomas. Radiographically, they are strikingly well-delineated, leading to 
a benign differential diagnosis. The histology must fall into any of these five 
patterns: 
1) At least 75% of the tumour mass should be composed of cells 
arranged in synctial sheets. Focal necrosis and squamoid 
differentiation can be seen. 
2) No gland or tubule formation is allowed. 
3) Diffuse infiltration of lymphocytes that is dense enough to obscure the 
tumour or in sparse amounts. 
4) The cells have abundant cytoplasm and moderately to markedly 
pleomorphic vesicular nuclei with numerous mitoses. 
5) These tumours are well-circumscribed, a feature that is obvious on 
low-power histological examination. 
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Immunohistochemistry: 
These tumours have a high proliferative index and are both ER and HER2 
negative. These tumour cells have been found to be correspond to T-
lymphocytes. BRCA1 mutations have shown an association with these 
tumours. The prognosis has been better in these cases than IDCs due to 
limited spread. 
MUCIN-PRODUCING CARCINOMAS: 
These tumours are often seen in women over the age of 60 years. On 
mammography, these tumours are well-delineated with lobulation. On gross, 
the external surface is bosselated while the cut surface is gelatinous and 
glistening. Histologically, proliferating tumour cells are seen in clusters, 
floating in pools of mucin. Thin fibrovascular septae divide the tumours. The 
mucin stains positively with mucicarmine. Pure mucinous carcinomas are of 
cellular and hypocellular type. Neuroendocrine differentiation and 
intracytoplasmic mucin is seen in the cellular type. The proportion of non-
mucinous type must be recorded in mixed tumours. 
These tumours are ER and PR positive as a general rule. The pure form has a 
better prognosis than the mixed subtype. Death due to mucin emboli leading 
to cerebral infarction has been reported in literature. 
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Mucinous adenocarcinoma and columnar cell mucinous carcinoma: 
These tumours are composed of tall columnar cells with bland basal nuclei 
and abundant intracytoplasmic mucin. Depending on their consistency, they 
are classified as Mucinous Cystadenocarcinoma (Cystic) or columnar cell 
mucinous carcinoma (solid) 
Two types of signet ring carcinoma are seen: 
i) Lobular type, with intracytoplasmic mucin 
ii) Related to diffuse gastric carcinoma with intracytoplasmic acidic 
mucin. 
NEUROENDOCRINE TUMOURS: 
They comprise 2 to 5% of all breast carcinomas. These tumours occur in the 
sixth decade or later and are occasionally also seen in males. 
Patients with small cell carcinomas are detected in advanced stage. These 
tumours infiltrate or are expansile with a gelatinous cut surface.  
Histopathologically, the cells are arranged in sheets or lobules with 
peripheral palisading.28 26% of the tumours are mucin producing. 
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Types: 
Solid: 
Here, the cells are spindled, plasmacytoid or large with intervening delicate 
fibrovascular septae. Carcinoid-like rosette formation may be seen. Mitoses 
varies from 4 to 12/hpf with focal necrosis and neuroendocrine granules. 
Small cell/oat cell carcinoma: 
Similar to their counterparts in the lung, these tumours are composed of cells 
with scanty cytoplasm and hyperchromatic nuclei with nuclear streaming 
and overlapping. 
Large cell Neuroendocrine tumours: 
This variant shows increased mitoses (18 to 65/hpf). Foci of necrosis are 
often seen. 
Differential diagnosis: 
Breast primary neuroendocrine tumours should be differentiated from 
metastatic carcinoids and small cell carcinomas. Breast Neuroendocrine 
tumours are Cytokeratin 7 positive and Cytokeratin 20 negative whereas 
both markers are negative in pulmonary carcinoids. ER, PR, GCDFP 15 are 
expressed in breast cancers. Breast neuroendocrine tumours show positivity 
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for E-cadherin while lobular carcinomas, a close differential of small cell 
carcinomas are negative. Neuroendocrine markers are positive in at least 
50% of the cells. Neuron specific enolase (NSE) is more sensitive than 
chromogranin A and synatophysin. TTF-1 and somatostatin receptors have 
also been demonstrated. 
Electron microscopy demonstrated dense core granules (chromogranin) and 
clear vesicles (synaptohysin). Mucinous differentiation bodes good 
prognosis. Histological grading is an important parameter for assessing 
prognosis with small cell neuroendocrine tumours considered 
undifferentiated carcinomas. 
INVASIVE PAPILLARY CARCINOMA: 
They comprise less than 1% of all breast carcinomas and have relatively 
good prognosis. These affect post-menopausal women. They are well-
circumscribed in two-thirds of the cases.  
Histologically, these tumours often exhibit Grade 2 histology. The cells are 
arranged in papillary pattern with focal solid areas. Calcification is noted, 
especially in cases with DCIS. More than 75% of the cases have DCIS, 
usually of the papillary type. Lymphatic invasion and nipple involvement are 
occasionally seen. 
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INVASIVE MICROPAPILLARY CARCINOMA 
These tumours have high rates of axillary node involvement. The neoplastic 
cells are arranged in clusters within large lacunae. Inside-out morphology or 
reverse polarity is seen often within the clusters. Vascular invasion is 
another common feature. 
APOCRINE CARCINOMA 
More than 90% of the neoplastic cells must show morphological and 
immunohistochemical evidence of apocrine features to warrant this 
diagnosis. Any morphological type (tubular/medullary/ papillary/ 
neuroendocrine) can express apocrine differentiation. Two types of cells 
have been recognized: Type A cells have abundant intensely eosinophilic 
granular cytoplasm. This type, also referred to as myoblastomatoid type, has 
granules which are PAS positive with diastase resistance and they resemble 
granular cell tumours. 
Type B cells have foamy cytoplasm, reminiscent of sebaceous cells and 
histiocytes. These tumours are ER, PR negative and GCDFP-15 positive. 
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METAPLASTIC CARCINOMA 
These tumours have an admixed population of squamous, spindled or 
mesenchymal cells. They are classified as purely epithelial or mixed 
epithelial and mesenchymal tumours.  
Pure epithelial cells have the following subtypes 1)Squamous cells (Large 
cell keratinizing, spindle cell, acantholytic) 2)Adenosquamous 
Mixed epithelial-mesenchymal tumours are  
1) Carcinoma with chondroid metaplasia 
2) Carcinoma with osseous metaplasia 
3) Carcinosarcoma 
SQUAMOUS CELL CARCINOMA 
Keratinizing, non-keratinizing, spindle and acantholytic cells may be seen in 
varying combinations. Desmoplastic stromal reaction is pronounced. 
Metastatic foci show squamous differentiation as well. 
Immunohistochemistry is required to confirm the epithelial nature of 
spindled and acantholytic variants. Broad and High Molecular Weight 
Cytokeratins serve this purpose. 
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Adenosquamous carcinoma: 
These tumours have a discernible glandular population admixed with solid 
nests of squamous cells. The squamous cells are hormone receptor negative 
while the glandular component’s positivity depends on the degree of 
differentiation. 
Mixed epithelial/mesenchymal metaplastic carcinomas: 
These tumours are also called matrix-producing carcinomas and consist of 
both carcinomatous and mesenchymal elements. Grading depends on the 
nuclear features. The spindle cells may be positive for cytokeratins focally. 
ER, PR may show positivity in the ductal elements depending on the 
differentiation. 
The differential diagnosis depends on the sarcomatous portion of the 
tumours. 
LIPID-RICH CARCINOMA 
In these tumours, more than 90% of the cells have abundant 
intracytoplasmic neutral lipid. These tumours must be differentiated from 
other tumours with clear cytoplasm. They tend to be high grade (Grade III) 
and invasive. The cytoplasm stains negatively for mucins 
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SECRETORY CARCINOMA 
These tumours are well-circumscribed and small. Pushing margins are 
identified. 
Histologically, the central portions of the tumour show prominent 
hyalinization. Tubuloalveolar and focal papillae lined by cells with 
vacuolated cytoplasm are seen. Prominent nucleoli and scanty mitotic 
figures are other features. 
ONCOCYTIC CARCINOMA 
These tumours have an oncocytic cell population comprising more than 
70%. These swollen cells have more than 60% of the cell comprising of 
mitochondria, which impart the granular eosinophilic character to the 
cytoplasm.  
Differential diagnosis: Immunophenotyping is necessary to distinguish 
between oncocytic myoepithelial, apocrine and neuroendocrine tumours. 
ADENOID CYSTIC CARCINOMA 
These are of low aggressive potential unlike their salivary gland 
counterparts. They present as discrete nodules which may be tender or 
cystic. Microscopically, three patterns have been described: trabecular-
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tubular, solid and cribriform. Two types of cells are noted; the basaloid cells 
and luminal cells. Adenoid cystic carcinomas tend to be negative for 
hormone receptors. These tumours have to be differentiated from benign 
collagenous spherulosis and cribriform carcinomas. 
ACINIC CELL CARCINOMA 
These rare tumours show serous (acinic cell) differentiation. Histologically, 
cells are arranged in microcystic and microglandular patterns. The cells have 
abundant granular eosinophilic cytoplasm with an irregular ovoid nucleus. 
The mitotic count can be high (up to 15/hpf). 
GLYCOGEN-RICH CLEAR CELL CARCINOMA (GRCC) 
In this tumour, abundant intracytoplasmic glycogen is seen in over 90% of 
the cells. The tumours that come in the differential are lipid-rich carcinoma, 
adenomyoepithelioma, metastatic clear cell carcinoma and clear cell 
hidradenoma. Very few of these tumours are of Grade 1, with most falling 
into 2 or 3. 
SEBACEOUS CARCINOMA 
These are a rare subset of tumours similar to adnexal tumours with 
sebaceous differentiation. Cutaneous derivation must be ruled out. The cells 
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are arranged in nests or lobules with abundant vacuolated cytoplasm. A 
second population of small spindle cells with eosinophilic cytoplasm is seen 
at the periphery. Squamoid morules are occasionally seen. 
INFLAMMATORY CARCINOMA 
These cancers have a characteristic clinical presentation. Lymphatic 
obstruction by the underlying IDC or infiltration into the dermal lymphatics 
results in this. These tumours are automatically staged as T4d. It is important 
to recognize that these are not true inflammatory conditions but 
malignancies which often have Grade 3 morphology. The survival rates are 
very poor for this subtype. 
NOTTINGHAM MODIFICATION OF SCARFF-BLOOM-
RICHARDSON GRADING:8 
This is a semi-quantitative grading system proposed by Ellis and Elston.  
Tubule formation 
1 point >75% 
2 points 10-75% 
3 points <10% 
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Nuclear pleomorphism 
1 point minimal pleomorphism 
2 points moderate pleomorphism 
3 points marked pleomorphism 
 
Mitotic count: 
Assignment of mitotic counts depends on the field area under examination: 
Field diameter (mm) 0.44 0.59 0.63 
Field area (mm2) 0.152      0.274        0.312 
Mitotic count    
1 point 0-5 0-9 0-11 
2 points 6-10 10-19 12-22 
3 points >11 >20 >23 
 
GRADES: 
Grade 1: well-differentiated breast carcinoma: 3-5 points 
Grade 2: moderately differentiated breast carcinoma: 6-7 points 
Grade 3: poorly differentiated breast carcinomas: 8-9 points 
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TNM STAGING OF BREAST CARCINOMAS:29 
Primary Tumor (T)  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis: Carcinoma in situ 
Tis (DCIS): Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget’s): Paget’s disease of the nipple NOT without association with  
IDC, DCIS or LCIS 
Carcinomas in the breast parenchyma along with Paget’s diease are staged 
based on the size and characteristics of the underlying parenchymal disease. 
However, the presence of Paget’s disease should be noted. 
T1 Tumor ≤ 2 cm in greatest dimension 
T1mi Tumor ≤ 1 mm in greatest dimension 
T1a Tumor > 1 mm but ≤ 0.5 cm in greatest dimension 
T1b Tumor > 0.5 cm but ≤ 1 cm in greatest dimension 
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T1c Tumor > 1 cm but ≤ 2 cm in greatest dimension 
T2 Tumor > 2 cm but ≤ 5 cm in greatest dimension 
T3 Tumor > 5 cm in greatest dimension 
T4 Tumor of any size; extension into the chest wall and/or into the skin with 
ulceration is noted. 
Note: Dermal invasion alone does not qualify as T4 
T4a Extension into the chest wall, more than just  
pectoralis muscle adherence/invasion 
T4b Ulceration or ipsilateral satellite nodules and/or  
peau d’orange of the skin, not meeting criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Staging of N: 
Nx: Regional lymph nodes cannot be assessed  
N0: No regional lymph node metastases 
N1: Metastases in movable ipsilateral level I, II axillary nodes 
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N2a: Metastases in fixed/matted ipsilateral level I, II axillary lymph nodes 
N2b: Metastases only in ipsilateral internal mammary nodes but with 
absence of clinically evident level I, II axillary lymph node metastases 
Staging of M 
N3a: Metastases to ipsilateral infraclavicular node(s) 
N3b: Metastases to ipsilateral internal mammary node(s) and axillary lymph 
node(s) 
N3c: Metastases to ipsilateral supraclavicular lymph node(s) 
PATHOLOGIC (PN) 
pNX:  Regional nodes cannot be assessed due to previous removal or for 
similar reasons 
pN0: No regional nodal metastasis on histopathological examination 
pN0(i−): with negative immunohistochemistry. 
pN0(i+) Tumour cells in regional lymph node(s) less than 0.2 mm (detected 
by H&E or IHC) 
pN0(mol−): negative molecular findings by using RT-PCR 
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pN0(mol+): Positive molecular findings on using RT-PCR, but without 
histological or immunohistochemical findings. 
pN1a:  Metastases in 1–3 axillary lymph nodes, with at least one being 
greater than 0.2 cm 
pN1b: Metastases in internal mammary nodes detected by sentinel lymph 
node biopsy and not clinically detected 
pN1c: Metastases in 1–3 axillary lymph nodes, internal mammary lymph 
nodes  detected by sentinel lymph node biopsy and not clinically detected. 
pN2a: Metastases in 4–9 axillary nodes, with at least 1 tumor deposit > 0.2 
cm. 
pN2b: Metastases in clinically detected internal mammary lymph nodes in 
without axillary nodal metastases. 
pN3a: i) Metastases present in ≥10 axillary lymph nodes (with at least 1 
tumor deposit >2.0 mm). ii) Metastases to infraclavicular lymph node. 
pN3b: i) Metastases in ipsilateral internal mammary nodes (clinically 
detected) with involvement of one or more axillary lymph nodes.ii) 
Metastases in >3 axillary lymph nodes and in internal mammary lymph 
nodes with sentinel lymph node biopsy but not clinically seen. 
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pN3c: Metastasis in the ipsilateral supraclavicular node. 
Distant metastasis (M):  
M0: No evidence of distant metastases (clinically and radiographically). 
cM0 (i+): No radiographic/clinical evidence of distant metastases, but 
molecularly or microscopic detection tumor deposits in circulating blood, 
bone marrow, non-regional nodal tissue that are ≤0.2 mm 
M1: Distant detectable metastases determined clinically or radiographically 
and/or histological evidence of deposits >0.2 mm. 
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TNM STAGING OF BREAST CARCINOMAS:29 
Stage  T  N  M  
0 Tis N0 M0 
IA T1b N0 M0 
IB T0 N1mi M0 
 T1b N1mi M0 
IIA T0 N1c M0 
 T1b N1c M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
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Stage  T  N  M  
 T1b N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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PROGNOSTIC AND PREDICTIVE FACTORS 
The major prognostic factors are the ones that determine the staging of 
breast cancer. 
1) Invasive versus in situ: In situ carcinomas have a chance of being 
completely cured in a majority of women in comparison with their 
invasive counterparts that have a greater incidence of invasion and 
death. 
2) Distant metastases: Complete cure is usually not possible in these 
tumours as a rule. The histological and molecular subtype determines 
the timing of distant metastases30,31. 
3) Lymph node status: 
This is the most important prognostic factor if distant metastases is 
absent32. The prognosis worsens as more lymph nodes show tumour 
deposits. Even micrometastasis (<0.2 cm) demonstrated by 
immunohistochemistry show shortened disease-free periods. Sentinel 
node biopsies, with use of radiotracer or dyes, are indicative of nodal 
spread in most cases. However, if the sentinel node is the internal 
mammary node, the procedure cannot be done.33,34 
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4) Tumour size: 
Assessing microscopic size (indicative of both invasive and in situ 
components) is more predictive of nodal metastasis. Tumours become 
palpable once they are over 2 cm in size. However, at this stage, the 
survival rate is less than 77% 
5) Locally advanced disease: 
Skin and skeletal muscle involvement interferes with complete 
surgical resection and increases the stage of the disease. 
6) Inflammatory carcinoma: 
Dermal lymphatic involvement can lead to “peau d’Orange” 
appearance due to skin thickening in Inflammatory breast cancers. 
These cancers, seen commonly in young and black women, have an 
extremely poor prognosis.35 
MINOR PROGNOSTIC FACTORS: 
1) Histological type: 
Similarly-sized tumours of tubular, mucinous, cribriform, papillary, 
adenoid cystic subtypes are found to have better prognosis than IDC 
of the non-specific type.36 
2) Histological grade: 
The long term survival drops from 70% for Grade I carcinomas to 
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45% for Grade II carcinomas. Higher grade tumours show better 
response to certain types of chemotherapy. 
3) ER/PR status: 
If both ER and PR are positive, the response to hormonal therapy is 
80% 
4) HER2neu:  
Overexpression is associated with lesser rate of survival but targeted 
therapy such as trastuzumab and Lapatinib have been developed. 
5) Lymphovascular invasion: 
Presence of tumour cells within small vascular channels have been 
found in over half the invasive tumours and are predictive of lymph 
node invasion and recurrence. Extensive involvement of dermal 
lymphatics is seen in inflammatory carcinoma. 
6) Proliferative rate: 
This can be assessed by:- 
i) Light microscopy-assessing mitotic count. 
ii) Flow cytometry- S-phase fraction can be gated and assessed. 
iii) Ki67/Mib index- detects cells in G1 through M phases of the 
cell cycle (actively proliferating cells). 
iv) Thymidine labelling index 
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v) RT-PCR: Highly proliferative tumours have poorer prognosis 
but good response to chemotherapy. 
7) Perineural invasion:  
This feature has been observed in invasive tumours. 
8) Tumour necrosis: 
If observed within the first two years of diagnosis, this parameter has 
been associated with poor prognosis. 
9) Tumour stroma: 
Foci of fibrosis within the centre of a tumours has been associated 
with poor prognosis. 
10) Response to neoadjuvant chemotherapy: 
Prior to surgery, the patient is treated with chemotherapy to 
downstage the carcinoma. Good response has good prognosis. High 
grade tumours with necrosis and negative HER2 status tend to 
respond well to chemotherapy. 
11) Gene expression: 
The expression of BRCA 1 is associated with worse prognosis. 
Allison et al summarized that Luminal A molecular subtype is 
associated with good prognosis, Luminal B with intermediate 
prognosis and both HER2 and Basal subtypes with worse prognosis. 
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Immunohistochemistry: 
Markers used in breast cancers are of two types:  prognostic and predictive 
markers. 
The routine markers used in surgical pathology for cases of breast cancer are 
ER, PR and HER2/neu. 
As per the ASCO guidelines, a panel of markers has been recommended by 
Harris et al.37 CA 15-3 and CA 27.29 are used for screening, diagnosis and 
also for surveillance. Estrogen and Progesterone receptors are recommended 
for all primary breast carcinomas and for metastatic carcinomas. Similarly, 
HER2 estimation is recommended in every case of primary breast cancer. It 
helps in selecting patients for Trastuzumab therapy and predicts response 
taxane therapy. A special mention is made about Oncotype DX which helps 
in identifying patients manageable with Tamoxifen alone or if adjuvant 
chemotherapy is necessary. 
Estrogen Receptors:  
These weakly predict the prognosis but strongly predict response to 
endocrine therapy.38 Nadji et al, in a study of nearly 6000 cases have shown 
that nearly all cases of Grade I tumours are ER positive, as are tubular, 
lobular and mucinous carcinomas. Progesterone receptors are independent 
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markers whose positivity signals better disease free survival. As these are 
therapeutic targets, quantitative assessments are critical. However, studies 
have demonstrated the need for meticulous standardization of technique and 
analysis, so that results are uniform.39 Factors that lead to variations are   
i)Type of specimen and fixative: 
Mann et al have shown that 9% of resection specimens show false negative 
ER due to inadequate fixation.40 A minimum of 6 to 8 hours of fixation has 
been recommended prior to immunohistochemical studies. This problem can 
be circumvented by comparing with the ER-status of the adjacent non-
neoplastic breast parenchyma. 
ii)Antibody used: 
SP1 rabbit monoclonal antibody has been shown by studies to have the most 
robust response.41 Other clones of anti-ER antibodies that are recommended 
are 1D5 and 6F11. Studies by Harvey et al have shown that 
immunohistochemistry is better than Ligand-Binding Assay for predicting 
response to Tamoxifen therapy.42 
Traditionally, the charcoal and sucrose gradient assays have been used. 
Quicgel method has been utilized in standardization. Two parameters are 
evaluated in immunohistochemistry. 
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i. Number of tumour cell nuclei stained 
ii. intensity of the reaction. 
The Allred scoring system is a nine-point system established through a 
landmark study conducted by Harvey et al. A score of 3 or more has been 
considered as ER positivity.38,43 
Score for proportion staining Score for staining intensity 
0=No nuclear staining 0=No staining 
1 = <1% nuclei staining 1=Weak staining 
2 = 1-10% nuclei staining 2 = Moderate staining 
3 = 11-33% nuclei staining 3 = Strong staining 
4 = 34-66% nuclei staining   
5 = 67 – 100% nuclei staining  
 
The discovery of these markers has been a cornerstone in breast cancer 
therapeutics. Radical estrogen-ablative therapies such as oopherectomy, 
pituaitary gland and adrenal removal have been abandoned in favour of 
Tamoxifen.44 Not only do these markers predict response, but also provide 
clues during diagnosis of metastatic tumour with unknown primary. Cases of 
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DCIS that are hormone positive have been controlled with the use of 
Tamoxifen.45 
However, the expression of ER alone does not predict the response to 
treatment. To increase the usefulness, a PR expression study must also be 
done in conjunction. 
Laake at al46 in 2000 established prognostic indices using ER scoring: 
Score 0: Endocrine treatment will definitely not work. 
Score 2-3: 20% chance of response to endocrine treatment 
Score 4-6: 50% chance of response 
Score 7-8: 75% response rates. 
Elderly women have shown some tumour shrinkage after endocrine 
treatment, even though ER scoring is low. 
Human Epidermal Receptor Protein-2: 
This is both a predictive and prognostic marker. Synonymous with c-erbB-2, 
this oncogene protein is transmembrane glycoprotein. These epidermal 
growth factor receptor proteins are expressed in various normal epithelia 
(including mammary ducts). Their overexpression due to amplification of 
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the HER2 gene is seen in a subset of breast malignancies. Since 10 to 20% 
of primary breast malignancies show overexpression39, it is now widely 
utilized as a predictive marker. Both immunohistochemistry and FISH 
studies are used to identify. Trastuzumab is a custom-made 
chemotherapeutic molecule that targets the oncogene product. Their use in 
early breast cancers has shown reduction of recurrence risk by 50% and 
mortality by one-third39. This anti-c-erbB2 antibody was introduced 13 years 
after the discovery of c-erb-B2. 
Discordance rates between immunohistochemistry and FISH results up to 
20% have been noted. In order to address this issue, the ASCO/CAP 
guidelines for reporting HER2 are as follows: 
FDA Scoring System for HER247 
Negative = 0  No immunostaining 
      1+   Weak immunostaining, <30% of the tumour cells  
Equivocal = 2+ Complete membranous staining, either uniform or     
weak in at least 10% of cells                                      
Positive = 3+  Uniform intense membranous staining at least 30% 
    of cells. 
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Strong membranous staining is taken as positive and diffuse cytoplasmic or 
background staining is disregarded.  In equivocal cases, FISH studies have 
been recommended.  
As per ASCO/CAP guidelines, the relative exclusion criteria are i) use of 
fixatives other than Neutral Buffered Formalin ii) Core needle biopsies fixed 
for less than one hour and large specimens less than 6 hours. ii) Any 
specimen fixed longer than 48 hours. The absolute rejection criterion is the 
presence of crush or edge artifact. 
Basal-like Breast Carcinoma: 
The definition of basal cells in the breast has been changing and argued over 
in the past years. In 2009, Rakha et al did a review of Basal-Like Breast 
Cancers1. They cite that in addition to the myoepithelial cells and luminal 
secretory cells, a third population of ‘basal’ cells are located in the luminal 
aspect of the TDLUs and large ducts. 48 
These cells express High Molecular Weight Cytokeratins (or ‘basal’ 
cytokeratins) but lack evidence of myoid differentiation. In normal breast, 
the term basal refers to both the myoepithelial cells and the aforementioned 
subset.  In breast cancer, tumour cells expressing high-molecular weight 
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cytokeratins are of ‘basal’ origin. The basal differentiation of tumours was 
described as early as 1982 by Moll et al.49  
These tumours are associated with Grade 3 histology; the tumour cells are 
highly pleomorphic and seen arranged in sheets with necrosis and 
inflammation, with lack of in situ components.50 They form around 15% of 
all breast carcinomas and have poor prognosis. Lack of response to 
Tamoxifen, Aromatase inhibitors and Trastuzumab is distinctive. 
 These aggressive tumours tend to occur in younger women, with only 
cytotoxic chemotherapy being the treatment modality, apart from surgery.51 
Histologically, a great degree of heterogeneity is noted in Basal-like breast 
cancers. Even though high-grade IDC is seen most frequently, prognostically 
favourable variants such as adenoid cystic have been associated with this 
genetic subtype.  
These were initially diagnosed by gene expression profiling through 
microarray-based techniques. However, this is not feasible in every set up. 
With low histological concordance rates and only expensive methods of 
recognition, it has important to develop practical biomarkers. Retrospective 
studies are being conducted on a large-scale to identify biomarkers which 
can translate into targets for therapy or at least predict the risk. 
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Sutton et al have concluded that 91% of basal-like cancers are EGFR 
positive. Clinical trials using Cetuximab, a chimeric monoclonal anti-EGFR 
antibody is being tested in metastatic tumours along with Gefitinib.52 
 Sorlie et al revealed a panel for basal-like breast cancers; there was high 
expression of Cytokeratin 5, HER1, cKIT and absence of ER and HER2.53 
Korsching et al54 and Bocker et al55 emphasized that the basal-like stem cell 
expresses CK 5/6 preferentially.   
Studies led by Lakhani et al have concluded saying that 88% of the patients 
with BRCA1 genotype expressed basal Cytokeratin 5/6. Both subsets have 
been associated with poorer prognosis. Since the cost of genetic testing is 
high, it cannot be executed in all patients of breast carcinoma with ease. 
Family history alone cannot be used as a valid indicator for genetic testing. 
A screening test to isolate women who are ER negative and CK 5/6 positive 
has been recommended.56  
The basal Cytokeratin used in our study was CK 5/6. Basal cytokeratins 
show cytoplasmic positivity and were interpreted as positive when more 
than 1% of the cells took up the immunostain. 
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Based on studies conducted by Rakha et al57, Laakso et al58, Van de Rijn et 
al59, an arbitrary scoring system was drawn up for quantifying the expression 
of CK 5/6. 
Score Description 
0 Less than 1% positivity 
1+ 1-10% tumour cells are positive 
2+ 10 to 50% tumour cells are positive 
3+ More than 50% tumour cells are positive 
 
CLINICAL CONSEQUENCES OF CK 5/6 EXPRESSION STUDIES: 
Apart from its use as a prognostic index, the various consequences of 
studying this marker’s expression has been extensively discussed. The 
regular tri-panel consisting of ER, PR and HER2 has been deemed 
suboptimal in defining basal-like breast carcinomas. Even though Triple 
Negative Breast Cancers are the rough equivalents of Basal like breast 
carcinomas, the overlap is considered imperfect at best. 60 
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Identification by immunohistochemical panels and molecular genetics aids 
in tailored therapeutics. A basal marker is necessary to differentiate between 
the two subgroups. TNBCs are mostly tumours with Grade 3 histology and 
nearly 48.6% of the patients require chemotherapy when compared with 
other subtypes.61 Response has been noted in basal-like breast cancers 
treated with PARP inhibitors and Cisplatin. These platinum-based salts 
interfere with the BRCA1 pathway and induce response.61,63 
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MATERIALS AND METHODS 
Our study is a retrospective study. Cases of female breast carcinomas 
diagnosed between the years 2009 and 2014 were included. A few of the 
cases were rejected owing to the absence of sufficient clinical information or 
blocks were unavailable. Trucut biopsies were excluded. 
The requisition form sent by the surgeon was used for deriving information 
such as age, site, nodal status and other gross findings. Retrieval of 
representative paraffin blocks and corresponding Haematoxylin & Eosin 
stained slides were done from the archives of the department of Pathology.  
For the purpose of H&E staining, the representative blocks were utilized for 
making 4-micron thick sections and stained using a Leica Autostainer. These 
H&E stained slides were used for grading and assessing the histological type 
of tumour. Evidence of lymphovascular invasion, perineural invasion, skin 
involvement and admixed DCIS components were assessed and tabulated in 
the master chart.  
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HAEMATOXYLIN AND EOSIN STAINING 
REAGENTS USED: 
1. Harris haematoxylin 
2. Eosin Y 
PROCEDURE: 
1. Deparaffinisation: Xylene is used. 
2. Hydration: The cut sections are hydrated by immersing in graded 
alcohols and bringing to water. 
3. Haematoxylin staining: Slides are flooded with Harris Haematoxylin 
for 10 minutes. 
4. Running tap water is used to wash the haematoxylin-stained slide for 
5 minutes (the sections should turn blue) 
5. Differentiation: 1% Acid Alcohol (1% hydrochloric acid in 70% 
alcohol) is used to flood the slides for 10 seconds. 
6. Tap water is used to wash the slides for 10 minutes. 
7. The slide is immersed in ammonia water and then washed with tap 
water for 5 minutes. 
8. Eosin: The slides are stained with Eosin Y for 10 to 15 minutes. 
9. The stained slide is washed in running tap water for three minutes. 
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10. Dehydration: The sections are dehydrated through graded alcohols. 
11. Clearing is executed with Xylene. 
12. DPX is used for mounting. 
Once H and E staining was completed, a review of the slides was executed 
to confirm adequacy and sections were cut from the representative blocks for 
the purpose of immunohistochemistry. 
Assessment was done on 4-5 micron-thick H& E stained sections. Typing 
and grading was done according to Modified Scarff-Bloom-Richardson 
grading system.8 The tumour was also evaluated for cytological pattern, 
skin involvement, perineural, and lymphovascular invasion. 
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IMMUNOHISTOCHEMICAL STAINING. 
Blocks of normal skin and prostatic tissue were taken as control blocks. 
These blocks were cut at 5-micron thickness and the sections were taken 
onto a Poly-L-lysine coated slide and utilized as positive control sections for 
Cytokeratin 5/6. Blocks were also cut and stained with ER, PR and 
Her2/neu, with positive controls for all three cases. 
The reagents used are as follows: 
Antibody  
Reagent 
Clone 
ER Clone EP1 by DAKO 
PR Clone PgR 636 by DAKO 
HER2/neu Anti-c-erbB-2 Clone CB11 by Biogenix 
CK 5/6 FLEX Monoclonal Mouse Anti-Human Cytokeratin 5/6 
(Clone D5/16 B4) 
 
TEST PRINCIPLE: 
The test is two-stage process. The first step involves the binding of the 
primary antibody to the targeted epitope in the tissue tested. The second step 
is to identify the bound primary antibody by using a secondary antibody by a 
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colorimetric reaction. The secondary antibody is bound to a dextran polymer 
with the help of horseradish peroxidase enzyme and an attached chromogen 
is responsible for the colour. 
Retrieval of the antigen9 
Formalin fixation leads to masking of specific antigens by cross-linkage. In 
order to expose these epitopes and optimize them for binding, antigenic 
retrieval has to be done. 
The various methods used for this are: 
1. Pressure cooked method. 
2. Proteolytic digestion method. 
3. Microwave method. 
For the purposes of this study, the pressure cooker method was used. The 
epitopes are unmasked by the action of both heat and pressure. Before this 
process is initiated, the slides were dewaxed and hydrated through graded 
alcohols. Antigenic retrieval was done in the pressure cooker for 10 minutes 
in EDTA buffer at an alkaline pH (pH 9). 
Reagents used: 
• Ethylene Diamine Tetra-acetic Acid (EDTA) buffer at ph 9. 
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• 3% Hydrogen peroxide in distilled water – this blocks the action of 
endogenous peroxidase and therefore prevents nonspecific 
background staining. 
• A solution of 0.01M Phosphate Buffered Saline (PBS) is prepared 
with a pH value of 7.6. The preparation is by combining the following 
substances in a litre of distilled water. 
1) Dibasic sodium phosphate, anhydrate 17.5 g 
2) Monobasic potassium phosphate, anhydrous 2.5 g 
3) Sodium chloride 17.0 g 
• Blocking: The reagent used is casein in BS with 15mM sodium azide. 
It blocks non-specific protein binding. 
• Primary antibodies against Cytokeratin 5/6 antigen. 
• Poly HRP reagent –Horse radish peroxidase enzyme.  
• DAB (3,3’ Diamino Benzidine tetra hydrochloride) is used as the 
chromogen. This is responsible for the permanent brown precipitate. 
• Harris Hematoxylin 
• Distrene dibutyl phthalate Xylene) – Mountant. 
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PROCEDURE 
1. Dewaxing of slides. 
2. Hydration through graded alcohol. 
3. Antigen retrieval: EDTA buffer is used at a pH of 9.0 for 10 minutes 
in a pressure cooker. 
4. Washing with running tap water. 
5. Washing in PBS buffer at pH 7.6 for 5 minutes. 
6. The excess buffer is wiped off and the slides are immersed in 0.3% 
hydrogen peroxide for 20 minutes in order to block the endogenous 
peroxidase enzyme. 
7. The slides are washed with PBS buffer three times for 5 minutes. 
8. Slides are incubated in blocking solution for ten minutes. 
9. The slides are washed with PBS buffer three times for 5 minutes. 
10. Slides are incubated with CK5/6 primary antibody for one hour. 
11. To improve the intensity, the sections are put in superenhancer for 30 
minutes.  
12. Slides are washed with PBS buffer three times for 5 minutes. 
13. Diamino Benzidine is used for eight minutes. 
14. Slides are washed with PBS buffer three times, 5 minutes each time. 
15. Counterstaining is done with Harris Hematoxylin, for 1 minute. 
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16. Slides are washed in running tap water. 
17. Sections are cleared with Xylene and mounted with DPX. 
The stained slides were then screened to analyze the expression of CK 5/6. 
External control was provided by skin and prostate sections whereas 
internal control was provided by nipple areolar complex and associated 
ductal hyperplastic cells. An arbitrary scoring system was drawn up, based 
on many studies, as there is no established scoring system for CK 5/6 in 
breast carcinomas. Any invasive tumour cell showing positive staining is 
taken as positive. 
DATA ANALYSIS: 
The various parameters entered into the masterchart were: 
i. Age of the patient. 
ii. Histological type of tumour 
iii. Size of the tumour 
iv. Grade 
v. Lymphovascular invasion 
vi. Perineural invasion 
vii. No. of lymph nodes showing evidence of metastasis 
viii. TNM staging 
ix. Involvement of surgical margins. 
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x. Staining properties of ER, PR, HER2/neu and CK 5/6. 
The information was entered into a Microsoft Excel Worksheet and 
extrapolated into statistical package SPSS, version 11.0. 
The Fisher’s Exact Test, Pearson’s Chi Square test, Likelihood ratio, 
Levene’s Test for Equality of Variances and T-test for Quality of means 
were the various statitistical tests used. 
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RESULTS AND OBSERVATIONS 
44 cases of female breast cancer were under study. The ages ranged between 
33 and 67 years.  The age group that had the most number of cases was the 
one with 41 to 50 year-old women. The commonest histological grade in our 
study was Grade 2, with 24 cases. 
Age group Grade I Grade II Grade III Total 
31-40 2 4 3 9 
41-50 3 8 4 15 
51-60 4 8 0 12 
61-70 2 4 2 8 
 11 24 9 44 
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CK 5/6 positivity in age and grade:  
Age Grade 1 Grade 2 Grade 3 
30-39 0 0 0 
40-49 0 6 0 
50-59 0 2 1 
60-69 0 1 0 
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23 out of 44 cases showed evidence of nodal metastasis (52%). Perineural 
invasion was seen in only two cases. Eight out of 44 cases showed 
involvement of the skin. Of these, one involved the nipple and one clear-cut 
case of Paget’s disease was observed. 20 out of 44 cases showed tumour 
emboli within the lymphatics and vascular spaces. 
Statistical correlation was seen between the size of the tumour and 
Cytokeratin 5/6 positivity by using Levene’s Test for Equality of Variances. 
Even though statistical correlation was not significant, we observed that 
higher grades were associated with a basal-like nature. 
 
 
 
 
 
 
 
 
Fig 1: IDC, Lipid-rich variant (H&E, 400 x)
Fig 2: Grade 3 IDC (H&E, 400 x)
Fig 3: Apocrine carcinoma of breast (H & E,100 x)
Fig 4: IDC with comedonecrosis. (H & E, 100 x)
Fig 5: Tubule formation < 10% (H & E, 100 x)
Fig 6: Grade 3 IDC with increased mitoses (H&E, 400 x)
Fig 7: Papillary Carcinoma of breast (H & E, 100 x)
Fig 8: IDC with perineural invasion (H & E, 100 x)
Fig 9: Subdermal lymphatic tumour emboli (H & E, 100 x)
Fig 10: IDC with ER nuclear positivity (IHC, 100 x)
Fig 11: IDC with  nuclear positivity for PR (IHC, 400 x)
Fig 12: IDC with complete strong membranous staining
for HER 2 (IHC, 400 x)
Fig 13: IDC with negative staining for CK 5/6 (IHC, 400 x)
Fig 14: IDC with less than 10% staining for CK 5/6 . DCIS
component shows positivity (IHC, 400 x)
Fig 15: IDC, with 10-50% of the cells show
cytoplasmic positivity for CK 5/6 (IHC, 400x)
Fig 16: IDC with >50% of the cells showing
cytoplasmic positivity for CK 5/6 (IHC, 400x)
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DISCUSSION 
Breast carcinomas have emerged as the most common malignancy in Indian 
women. Similarly high incidence is seen in South Indian population also, 
where they form one-third of all female cancers.64 Not only is their incidence 
high, but the fatality rate of these cases exceeds those of western population. 
The cure rates, quality and the length of life have improved in these women, 
after the development of targeted therapy. 
 Glass et al observed quantitative and qualitative trends in breast 
cancer incidence. There has been a tremendous increase, particularly in ER 
positive tumours.6 The reason for the exponential rise has been attributed to 
the use of post-menopausal hormone replacement therapy and widespread 
utilization of mammography. 
 The overall percentage of ER positive cases was 45%, lesser when 
compared with western literature. This is consistent with findings in a study 
conducted by Ambroise et al, which concluded saying that hormonal 
expression is lesser in the south Indian population.64 
 This stresses the need to look into other markers and their routine use 
in South Indian cohorts. 
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There are subsets of breast carcinoma which are not susceptible to 
conventional therapy and have a paradigm shift in molecular genetics and 
immunohistochemical expression. These are the Basal-like breast 
carcinomas and the Triple Negative Breast Cancers. 
Overall, the mean age of patients with breast cancer was studied by Sarrio et 
al and found to be 53 years.65 The mean age of the patients in our study 
being 52 years, this parameter also showed close correlation. 
Oral contraceptive usage for more than a year was also associated with a 2.5 
fold increase in incidence but there is no significantly increased risk for non-
Triple Negative Breast Cancers. In our study, history of OCP use and parity 
status was not available. 
Sarrio et al concurred that 53% of the tumours in their study showed lymph 
node invasion. 92.6% showed histological features of IDC. Grade 2 tumours 
formed 39% of the cohort while Grade 3 was 46%.  
In our study, similar results were seen. Around 88% of the cases were of the 
IDC histological type.  45% showed evidence of lymphovascular invasion. 
More than half the cases belonged to Grade 2.  
Barnes et al, in their study, determined that the receptor status in metastatic 
foci is similar to that of the primary tumour. This rule, however, does not 
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apply to cases which have been treated with adjuvant chemotherapy. ER 
positive tumours can generate ER negative metastasis.5 
Gown et al observed that HER2 oncogene protein is expressed at low levels 
in a variety of normal epithelia including the ductal epithelium of breast. It is 
the amplification of the gene and overexpression of the corresponding gene 
product that is relevant in determining HER2/neu status.43 
American Society of Clinical Oncologists and the College of American 
Pathology have recently released guidelines for laboratory testing of HER2 
status. Normalization technique was introduced for standardization of results 
and to avoid discordance between immunohistochemistry and FISH results. 
There is improved accuracy of HER2 studies using a subtraction scoring 
system in which a signal score of non-neoplastic breast epithelium is 
subtracted from that of the tumour. Using this system, the proportion of 
HER2 positive tumours in our study is 63% 
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Comparative analysis of results in studies conducted by Harvey et al42 with 
ours 
Factor Harvey et al 
% of ER positive 
tumours 
Our study 
% of ER positive 
tumours 
Nodal status 
*Node negative 
*Node positive 
 
73 
68 
 
27.2% 
54% 
Tumour size, cm 
<2 
>2 
 
78 
67 
 
58.3% 
37.5% 
Patient age, in years 
<35 
35-65 
>65 
 
46 
65 
82 
 
100 
0 
48% 
  
From the above statistics, we inferred that due to the large size of the 
tumours in our study, there was increased nodal metastasis. Almost all the 
women with ER positive cases belonged to the 35 to 65 year age group.  
Dolle et al inferred that Triple Negative Breast Cancers (TNBCs) are breast 
cancer subtypes associated with high mortality rate and resistance to 
hormonal manipulation and Herceptin.66 Since these tumours are negative 
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for ER, PR and HER2, newer markers are to be identified for this subtype. 
These tumours have been seen with increased incidence in younger women 
(aged 45 years or younger). Our study showed close correlation, with the 
mean age of women with TNBCs being 46 years and nearly a third of the 
women were 40 or younger. These malignancies have also been associated 
with increased incidence in Black and Asian women, irrespective of the 
socio-economic status.67 
The purpose of our study was to identify a newer basal marker and observe 
the expression and clinicopathological in cases of breast cancer at our centre.  
A study led by Heatley showed that CK 7, CK8 and CK 19 were absent in 
carcinomas and the usage of these antibodies should serve as means to 
distinguish benign from malignant.4 CK 14 expression with absence of other 
myoepithelial markers has been reported.  
The basal marker that we selected for our study was CK 5/6. Clark et al 
suggested that CK5 is positive in breast progenitor cells68, which are 
believed to be the cell of origin in basal-like breast cancers1. Studies led by 
Sarrio et al, 15.24% of the patients in their study were of the basal-like 
subtype, with most of these tumours belonging to Grade 3. In our study, 
25% of the cases were basal-like, with all of these tumours falling into either 
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Grade 2 or Grade 3. In a large-scale research by Nielson and Choo, 14% of 
the cases were found to be positive for basal cytokeratins.51  
67% of the carcinosarcomas were basal-like. In our study, the only case of 
metaplastic tumour was negative for basal markers.  
Studies conducted by Beyer and Yeh have shown that not all cases of Triple 
Negative Breast Carcinomas (TNBCs) are basal-like70. In a study conducted 
by Sutton et al, CK 5/6 was expressed in 62% of TNBCs. In our study, CK 
5/6 was positive 50% of TNBCs. 
In a study led by Lakhani, cytokeratin 5/6 was positive in 7.83% of the 
cases.69 Their results compared with ours, is as follows: 
Grade of the tumour Ck 5/6 positivity rate
Statistics by Lakhani 
et al 
CK 5/6 positivity 
rate- our study 
1 0 0% 
2 0 37% 
3 12% 22% 
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The high rates in our study are explained by the considerable overlap 
between Grade 2 and Grade 3 tumours. As our cohort was entirely of the 
Asian population, we observed higher rates of basal marker positivity. 
In a study conducted by Nielson et al, nodal positivity in CK 5/6 was 
69.2%71 whereas the nodal positivity in basal cytokeratin positive cases in 
our study was nearly 80%. Vascular emboli were also prominent in these 
tumours, consistent with their highly invasive nature. 
Rakha et al conducted large-scale studies and found that 75 to 100% of 
basal-like tumours belonged to Grade 3. They inferred that these tumours are 
heterogeneous entities with distinctive morphological, histological and 
genetic characteristics. These malignancies are associated with poor 
prognosis and have a distinctive response to chemotherapy. They concluded 
their study by recommending a panel of four biomarkers for basal-like breast 
cancers: Ck5/6, CK 14, CK 17 and EGFR. 
However, Nielson et al observed that a panel consisting of ER, HER2 and 
CK 5/6 to identify the basal-like subset was useful as this 
immunnohistochemical combination had a 76% sensitivity and 100% 
specificity rate when compared with genetic microarray analysis.71 
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Cheang et al conducted the largest study as of date with 4046 patients and 
their results were similar to our study. 70% of tumours were of 50-62 year 
age group. 90.5% were of ductal. 5.2% were of Grade 1, 39% by Grade 2 
and 51% were Grade 3.72 The results are compared with our study and also 
with a study led by Laakso et al. The latter study used a cocktail of 
antibodies comprising of CK5/14, CK8/18 and p63. The parameters used in 
the comparative table below are those of the subset stained with antibodies 
to CK 5. 
Characteristics Cheang et al. 
statistics 
Our study statistics 
Age at diagnosis 
<40 
41-49 
50-65 
>65 
 
9.4% 
19% 
35.5% 
36.2% 
 
15.9% 
34% 
50% 
4% 
Histology 
Ductal 
Others 
 
90.5% 
9.5% 
 
88.7% 
11.3% 
Grade 
1 
2 
3 
 
5.2% 
39.1% 
51.1% 
 
25% 
54.5% 
20.5% 
Tumour size   
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<2 
2-5 
>5 
51.7% 
41.9% 
5.4% 
27% 
50% 
20.4% 
Lymphovascular 
invasion 
Positive 
Negative 
 
 
43.3% 
52.% 
 
 
45% 
55% 
 
As early as three decades back, the basal subset was described by Dairkee et 
al as tumours arising from progenitor/stem cells in the female breast.74 A 
series of studies ensued, each with its own threshold for basal Cytokeratin 
expression. Fulford et al75, Jones et al76, Banerjee et al77 and Abd El-Rehim 
et al78 deemed cases as positive if even a single cell showed staining. The 
various cytokeratins used were mostly CK 5/6, CK14, CK17 and antibody 
cocktails.  
 
 
 
 
 
109 
 
The conclusions drawn from the landmark studies are as follows:  
Authours of the 
study 
Conclusion 
Rakha et al CK 14 and/or CK 5/6 expression suffices to define 
basal-like breast cancer 
Jumpannen et al79 Expression has no impact on long-term survival if the 
tumours are ER-negative. 
Laakso et al True basal breast carcinomas are HER2 negative; 
CK5/6 expression has no prognostic use in high-risk 
patients. 
Van de Rijn et al Expression of basal cytokeratins was an independent 
prognostic factor in breast cancers with no axillary 
nodal metastasis 
 
Nielson et al 
 
 A panel of four antibodies (ER, CK 5/6, HER2 and 
EGFR) can identify breast carcinomas with accuracy. 
Jones et al breast carcinomas have an overall low disease-free 
survival and demonstrate a distinctive chromosomal 
pattern 
Fulford et al Overall survival was better in basal-like Grade 3 
carcinomas than their non-basal counterparts. The 
study also stressed that the risk of liver and bone 
metastases was lower in basal-like breast carcinomas. 
Our study CK5/6 positivity was seen in tumours of larger size 
and higher grades 
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LIMITATIONS OF THE STUDY 
1. A more accurate diagnosis of basal-like breast carcinoma can be made 
using a panel of immunohistochemical markers namely CK5/6, CK14 
and EGFR. However, data regarding ER, PR and HER2neu used in 
conjunction with CK 5/6 improves the specificity of CK 5/6 in 
detecting basal-like breast carcinomas. 
2. There is no uniform scoring system for CK 5/6 expression in breast 
carcinomas. An arbitrary scoring system was drawn up based on 
various studies. 
3. Details regarding therapeutic response and disease-free survival of the 
patients in our study were not available to us. 
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SUMMARY AND CONCLUSIONS 
¾ 18% of the breast carcinomas in our study were negative for 
ER, PR, and HER2neu and hence, come under the category of 
Triple Negative Breast Cancer (TNBC). 
¾ Out of these TNBCs, 50% were positive for CK 5/6. 
¾ CK 5/6 positivity showed significant statistical correlation with 
the size of the tumour.  
¾ All cases that were positive for CK 5/6 were of higher 
histological grade. 
Based on our study, we recommend the routine use of CK 5/6 in all cases of 
Triple Negative Breast Carcinomas as they help in identifying the basal-like 
subtype without relying on expensive tests based on molecular genetics. 
Despite poor prognosis, this cohort has good response to platinum and 
anthracycline based chemotherapy. More research is necessary to identify 
specific therapies for this subset. 
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MASTER CHART 
Age Slide no Histological type of tumour Size Grade LV invasion Perineural No of LN TNM staging Staging Margins ER PR Her2NEU CK 5/6
67 674/09 Infiltrating ductal, NOS 2 cm 2 or 3 No No 0/11 T1N0M0 IA No Negative Negative 2+ Positive
35 1677/10 Infiltrating ductal, NOS 3 3 No No 0/10 T2N0M0 IB No Negative Negative 3+ Negative
60 1702/10 Infiltrating ductal, NOS 3 1 Vascular No 3 out of 8 T2N1M0 IIB No Positive Negative Strong Negative
65 988/10 IDC,IPC,Micropapillary 2 2 No No 1 out of 8 T1N1M0 IA No Positive Positive 3+ Negative
59 4258/10 IDC, Paget's 3.5 1 Vascular No o/13 T2N0M0 IIA No Positive Positive Strong Negative
49 2909/10 IDC, intraductal papilloma 2.5 2 No No 7 out of 18 T2N2M0 IIIA No Negative Negative Strong Positive
40 4576/10 IDC, skin + 2 1 No No 1 out of 8 T4b N1M0 IIIB No Positive Positive Strong Negative
55 700/10 Micropapillary 4 2 No No 1 out of 11 T2N1M0 IIB No Negative Negative 3+ Negative
43 1407/10 IDC 6.5 3 No No 3 out of 8 T2N1M0 IIB No Negative Negative N/a Negative
38 254/11 IDC 4 3 No No 0/17 T2N0M0 IIA No Negative Negative 100% Negative
43 694/11 IDC w/ DCIS, UDH 1.5 1 No No 0/18 T1N0M0 IA No Positive Positive Strong Negative
56 438/11 IDC 1.8 2 Vascular No 3 out of 17 T1N1M0 IIA No Mod. Negative Strong Negative
55 2600/11 IDC 3.2 2 No No 2 out of 12 T3N1M0 IIIA No Negative Negative Strong Negative
52 2900/11 IDC, skin+ 4.5 2 Lymphatic No 8 out of 21 T4bN2M0 IIIB No Negative Negative Strong Negative
53 4116/12 IDC 5 1 No No 1 out of 17 T3N1M0 IIIA No Positive Positive Positive Negative
44 2708/12 IDC 2 2 No No 0/14 T1N0M0 IA No Negative Negative Strong Negative
49 4049/12 IDC 3.5 2 No No 0/14 T2N0M0 IIA No Negative Negative Strong Negative
40 2577/12 IDC, NOS 2.3 2 No No 8 out of 25 T2N2M0 IIIA No Positive Positive Strong Negative
62 4170/12 IDC, nipple+ Skeletal m+ 4.5 2 Vascular No N/A Yes Negative Negative Moderate Negative
66 3279/12 Invasive Papillary Ca 5 1 No No 0/32 T2N0M0 IIA No Negative Negative Moderate Negative
48 807/12 IDC 2.5 2 No No N/A T2N0M0 IIA No Weak Weak Negative Negative
44 4265/12 IDC 3.5 2 Vascular No 0/21 T2N0M0 IIA No <10 Negative Strong Positive 2
47 3840/13 IDC, NOS 3 2 or 3 Lymphovascular No 1 out of 19 T2N1M0 IIB No Positive Positive Strong Negative
Age Slide no Histological type of tumour Size Grade LV invasion Perineural No of LN TNM staging Staging Margins ER PR Her2NEU CK 5/6
64 3675/13 IDC 1 3 Lymphovascular Yes 5 out of 10 T1N1M0 IA No Negative Negative Strong Positive 2
51 1833/13 Metaplastic Ca 5 2 No No 0/25 T2N0M0 IIA No Negative Negative Negative Negative
58 4310/13 IDC 1.9 1 No No 0/9 T1N0M0 IA No Negative Negative Positive Negative
52 3600/13 IDC w/ keratin pearl 9 Yes No 11 out of 19 T3N2M0 IIIA No Negative Negative Positive Positive
40 135/14 IDC, skin involvement + 7.5 2 No No N/A T4b IIIB No Strong Strong Positive Positive 1
42 393/14 ILC 3.5 1 No No 0/16 T2N0M0 IIA No Strong Strong Weak Negative
53 533/14 IDC, Lipid-rich variant 7.5 2 Yes No 1 out of 19 T3N1M0 IIIA No Negative Negative Negative Positive 2
50 1037/14 IDC 1 3 Yes No 5 out of 5 T1N2M0 IIIA No, tumor deposits + Negative Negative Positive Negative
38 1159/14 Apocrine carcinoma 3.5 2 No No 0/26 T2N0M0 IIA No Negative Negative Negative Negative
45 4926/12 IDC, NOS 4.5 2 Yes No 1 out of 23 T2N1M0 IIB No Positive Positive Positive Positive
47 4797/10 IDC w/ lobular component 1 2 Yes No 1 out of 13 T1N1M0 IIA No Positive Positive Negative Positive
59 3646/09 IDC, NOS 6 2 No No 0/19 T3N0M0 IIIA No Negative Negative Positive Negative
55 3739/12 IDC, NOS 2.5 2 No No 0/40 T2N0M0 IIA No Positive Negative Positive Negative
37 653/10 IDC, NOS 6.5 3 Yes No 2 out of 15 T3N1M0 IIIA No Negative Negative Negative Negative
63 4634/10 IDC, skin+ 3.5 1 Yes No 7 out of 12 T2N2M0 IIIA No Positive Positive Negative Negative
62 2362/13 IDC, NOS, Skin + 8 2 Yes No N/A T3N0M0 IIIA No Positive Positive Negative Negative
63 2958/14 Mixed IDC and mucinous 4 2 Yes No 1 out of 11 T2N1M0 IIB No Positive Positive Negative Negative
50 1037/14 IDC, NOS 1 3 Yes No 5 out of 5 T1N1M0 IIB No Positive Positive Negative Negative
50 770/11 IDC, skin + 12.5 2 No No N/A T4NxM1 Yes Negative Negative Negative Positive 3+
40 3704/13 IDC 4 2 Yes No 1 out of 11 T3N1M0 IIIA No Negative Negative Negative Positive 1
48 4509/13 IDC, NOS 1.5 1 No No 0/16 T1N0M0 IA No Positive Positive Negative Negative
33 325/14 IDC 1.8 1 Yes Yes 0/18 T1N0M0 IA No Positive Positive Positive Negative
